Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20188691 | 1.00 | KMT2A (0.47) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL22457372 | 0.88 | PTPRA (0.48) | TSHRALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20190939 | 0.88 | PTPRA (0.48) | TSHRALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20188350 | 0.87 | KMT2A (0.49) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20188346 | 0.87 | KMT2A (0.49) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20188114 | 0.84 | CTRB1 (0.49) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20188112 | 0.84 | CTRB1 (0.49) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20190722 | 0.83 | PTPRA (0.44) | TSHRALDH1A1SMN1; SMN2CYP1A2CYP2D6 | |
| SCHEMBL20188307 | 0.82 | TSHR (0.47) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL20188303 | 0.82 | TSHR (0.47) | KMT2ATSHRALDH1A1SMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | claimed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | claimed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | claimed |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD. | 2020-09-24 | — | — | US | disclosed |
| WO-2018098344-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299238-A1 | PRODRUGS OF LANICEMINE AND THEIR METHOD OF USE | GRIN3A, GRIN1, GRM3 | KMT2A 1205/4885TSHR 2200/4885ALDH1A1 2783/4885 |
| US-11358935-B2 | Prodrugs of lanicemine and their method of use | GRIN3A, GRIN1, GRM3 | KMT2A 1205/4885TSHR 2200/4885ALDH1A1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.